Clinical trial · Observational
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
Health-Related Quality Of Life In Patients With Low Risk, Localized Prostate Cancer Randomized To Radical Prostatectomy Or Brachytherapy
NCT00052481CI-TRIAL-00022859completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy. PURPOSE: Randomized clinical trial to study quality of life in patients undergoing radical prostatectomy or brachytherapy for stage II prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| quality-of-life assessment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Quality of life questionnaire
- description
- Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy). Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071.
- interventionNames
- Procedure: quality-of-life assessment
Primary outcomes (1)
- measure
- time to treatment failure
- timeFrame
- Up to 10 years
Secondary outcomes (1)
- measure
- disease progression
- timeFrame
- Up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the prostate within the past 120 days * Stage II disease (T1c-T2a, N0, M0) * Concurrent enrollment on ACOSOG-Z0070 * Not yet randomized to an intervention arm (radical prostatectomy or brachytherapy) * Willing and able to complete heath-related quality of life questionnaires PATIENT CHARACTERISTICS: Age * 75 and under PRIOR CONCURRENT THERAPY: Endocrine therapy * More than 6 months since prior hormonal therapy for prostate cancer
References
Publications (0)
Data not yet available
No reference posted for this study.